The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Lymphocytes, Tumor-Infiltrating

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Lymphocytes, Tumor-Infiltrating


High impact information on Lymphocytes, Tumor-Infiltrating


Chemical compound and disease context of Lymphocytes, Tumor-Infiltrating


Biological context of Lymphocytes, Tumor-Infiltrating


Anatomical context of Lymphocytes, Tumor-Infiltrating


Associations of Lymphocytes, Tumor-Infiltrating with chemical compounds


Gene context of Lymphocytes, Tumor-Infiltrating


Analytical, diagnostic and therapeutic context of Lymphocytes, Tumor-Infiltrating


  1. Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. Rosenberg, S.A., Aebersold, P., Cornetta, K., Kasid, A., Morgan, R.A., Moen, R., Karson, E.M., Lotze, M.T., Yang, J.C., Topalian, S.L. N. Engl. J. Med. (1990) [Pubmed]
  2. In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial. Economou, J.S., Belldegrun, A.S., Glaspy, J., Toloza, E.M., Figlin, R., Hobbs, J., Meldon, N., Kaboo, R., Tso, C.L., Miller, A., Lau, R., McBride, W., Moen, R.C. J. Clin. Invest. (1996) [Pubmed]
  3. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Thompson, R.H., Gillett, M.D., Cheville, J.C., Lohse, C.M., Dong, H., Webster, W.S., Krejci, K.G., Lobo, J.R., Sengupta, S., Chen, L., Zincke, H., Blute, M.L., Strome, S.E., Leibovich, B.C., Kwon, E.D. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  4. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Sato, E., Olson, S.H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A.A., Frosina, D., Gnjatic, S., Ambrosone, C., Kepner, J., Odunsi, T., Ritter, G., Lele, S., Chen, Y.T., Ohtani, H., Old, L.J., Odunsi, K. Proc. Natl. Acad. Sci. U.S.A. (2005) [Pubmed]
  5. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Yoshino, I., Goedegebuure, P.S., Peoples, G.E., Parikh, A.S., DiMaio, J.M., Lyerly, H.K., Gazdar, A.F., Eberlein, T.J. Cancer Res. (1994) [Pubmed]
  6. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Wang, H.Y., Lee, D.A., Peng, G., Guo, Z., Li, Y., Kiniwa, Y., Shevach, E.M., Wang, R.F. Immunity (2004) [Pubmed]
  7. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. Robbins, P.F., El-Gamil, M., Li, Y.F., Kawakami, Y., Loftus, D., Appella, E., Rosenberg, S.A. J. Exp. Med. (1996) [Pubmed]
  8. Recurrent T cell receptor rearrangements in the cytotoxic T lymphocyte response in vivo against the p815 murine tumor. Levraud, J.P., Pannetier, C., Langlade-Demoyen, P., Brichard, V., Kourilsky, P. J. Exp. Med. (1996) [Pubmed]
  9. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P.F., Rivoltini, L., Yannelli, J.R., Appella, E., Rosenberg, S.A. J. Exp. Med. (1994) [Pubmed]
  10. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. Bakker, A.B., Schreurs, M.W., de Boer, A.J., Kawakami, Y., Rosenberg, S.A., Adema, G.J., Figdor, C.G. J. Exp. Med. (1994) [Pubmed]
  11. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. Rosenberg, S.A., Packard, B.S., Aebersold, P.M., Solomon, D., Topalian, S.L., Toy, S.T., Simon, P., Lotze, M.T., Yang, J.C., Seipp, C.A. N. Engl. J. Med. (1988) [Pubmed]
  12. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. Fisher, B., Packard, B.S., Read, E.J., Carrasquillo, J.A., Carter, C.S., Topalian, S.L., Yang, J.C., Yolles, P., Larson, S.M., Rosenberg, S.A. J. Clin. Oncol. (1989) [Pubmed]
  13. Gene therapy clinical trials worldwide 1989-2004-an overview. Edelstein, M.L., Abedi, M.R., Wixon, J., Edelstein, R.M. The journal of gene medicine. (2004) [Pubmed]
  14. Effect of indomethacin on tumor-infiltrating lymphocytes of a spontaneously developed murine mammary adenocarcinoma. Chao, T.Y., Chu, T.M. Cancer Immunol. Immunother. (1989) [Pubmed]
  15. Cultured breast cystosarcoma phylloides cells and applications to patient therapy. Lewko, W.M., Vaghmar, R., Maleckar, J.R., Husseini, S., Montgomery, C.A., Thurman, G.B., Oldham, R.K. Breast Cancer Res. Treat. (1990) [Pubmed]
  16. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. Bennett, M.W., O'Connell, J., O'Sullivan, G.C., Brady, C., Roche, D., Collins, J.K., Shanahan, F. J. Immunol. (1998) [Pubmed]
  17. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. Morgan, R.A., Dudley, M.E., Yu, Y.Y., Zheng, Z., Robbins, P.F., Theoret, M.R., Wunderlich, J.R., Hughes, M.S., Restifo, N.P., Rosenberg, S.A. J. Immunol. (2003) [Pubmed]
  18. Natural killer-cell activity under conditions reflective of tumor micro-environment. Loeffler, D.A., Juneau, P.L., Heppner, G.H. Int. J. Cancer (1991) [Pubmed]
  19. Shared amino acid sequences in the ND beta N and N alpha regions of the T cell receptors of tumor-infiltrating lymphocytes within malignant glioma. Ebato, M., Nitta, T., Yagita, H., Sato, K., Okumura, K. Eur. J. Immunol. (1994) [Pubmed]
  20. Selective homing of phenotypically lytic cells within nasopharyngeal carcinoma biopsies: numerous CD8- and CD16-positive cells in the tumor. Lakhdar, M., Ben Aribia, M.H., Maalej, M., Ladgham, A. Int. J. Cancer (1991) [Pubmed]
  21. In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. Griffith, K.D., Read, E.J., Carrasquillo, J.A., Carter, C.S., Yang, J.C., Fisher, B., Aebersold, P., Packard, B.S., Yu, M.Y., Rosenberg, S.A. J. Natl. Cancer Inst. (1989) [Pubmed]
  22. T-cell receptor repertoire in neuroblastoma patients. Valteau, D., Scott, V., Carcelain, G., Hartmann, O., Escudier, B., Hercend, T., Triebel, F. Cancer Res. (1996) [Pubmed]
  23. MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation. Toso, J.F., Oei, C., Oshidari, F., Tartaglia, J., Paoletti, E., Lyerly, H.K., Talib, S., Weinhold, K.J. Cancer Res. (1996) [Pubmed]
  24. Adoptive immunotherapy by pantropic killer cells recovered from OK-432-injected tumor sites in mice. Saito, M., Nanjo, M., Kataoka, M., Moriya, Y., Sugawara, Y., Yoshida, T., Ishida, N. Cancer Res. (1988) [Pubmed]
  25. Two mechanisms for tumor evasion of preexisting cytotoxic T-cell responses: lessons from recurrent tumors. Zheng, P., Sarma, S., Guo, Y., Liu, Y. Cancer Res. (1999) [Pubmed]
  26. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. Spiess, P.J., Yang, J.C., Rosenberg, S.A. J. Natl. Cancer Inst. (1987) [Pubmed]
  27. Lymphocytes as cellular vehicles for gene therapy in mouse and man. Culver, K., Cornetta, K., Morgan, R., Morecki, S., Aebersold, P., Kasid, A., Lotze, M., Rosenberg, S.A., Anderson, W.F., Blaese, R.M. Proc. Natl. Acad. Sci. U.S.A. (1991) [Pubmed]
  28. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Rubin, J.T., Elwood, L.J., Rosenberg, S.A., Lotze, M.T. Cancer Res. (1989) [Pubmed]
  29. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. Dudley, M.E., Wunderlich, J.R., Yang, J.C., Sherry, R.M., Topalian, S.L., Restifo, N.P., Royal, R.E., Kammula, U., White, D.E., Mavroukakis, S.A., Rogers, L.J., Gracia, G.J., Jones, S.A., Mangiameli, D.P., Pelletier, M.M., Gea-Banacloche, J., Robinson, M.R., Berman, D.M., Filie, A.C., Abati, A., Rosenberg, S.A. J. Clin. Oncol. (2005) [Pubmed]
  30. Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan. Mokyr, M.B., Rubin, M., Newell, K.A., Prokhorova, A., Bluestone, J.A. J. Immunol. (1993) [Pubmed]
  31. Involvement of both Tac and non-Tac interleukin 2-binding peptides in the interleukin 2-dependent proliferation of human tumor-infiltrating lymphocytes. Yagita, M., Itoh, K., Tsudo, M., Schaub, L.B., Platsoucas, C.D., Balch, C.M., Grimm, E.A. Cancer Res. (1989) [Pubmed]
  32. Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity. Dorothée, G., Vergnon, I., Menez, J., Echchakir, H., Grunenwald, D., Kubin, M., Chouaib, S., Mami-Chouaib, F. J. Immunol. (2002) [Pubmed]
  33. IL-3 affects endothelial cell-mediated smooth muscle cell recruitment by increasing TGF beta activity: potential role in tumor vessel stabilization. Dentelli, P., Rosso, A., Calvi, C., Ghiringhello, B., Garbarino, G., Camussi, G., Pegoraro, L., Brizzi, M.F. Oncogene (2004) [Pubmed]
  34. Growth stimulation of human head and neck squamous cell carcinoma cell lines by interleukin 4. Myers, J.N., Yasumura, S., Suminami, Y., Hirabayashi, H., Lin, W., Johnson, J.T., Lotze, M.T., Whiteside, T.L. Clin. Cancer Res. (1996) [Pubmed]
  35. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Konishi, J., Yamazaki, K., Azuma, M., Kinoshita, I., Dosaka-Akita, H., Nishimura, M. Clin. Cancer Res. (2004) [Pubmed]
  36. Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes. Rosenberg, S.A., Schwarz, S.L., Spiess, P.J. J. Natl. Cancer Inst. (1988) [Pubmed]
  37. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes. Ogasawara, M., Rosenberg, S.A. Cancer Res. (1993) [Pubmed]
  38. T-cell receptor zeta-chain expression on tumor-infiltrating lymphocytes from renal cell carcinoma. Cardi, G., Heaney, J.A., Schned, A.R., Phillips, D.M., Branda, M.T., Ernstoff, M.S. Cancer Res. (1997) [Pubmed]
  39. Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients. Valmori, D., Dutoit, V., Liénard, D., Lejeune, F., Speiser, D., Rimoldi, D., Cerundolo, V., Dietrich, P.Y., Cerottini, J.C., Romero, P. J. Immunol. (2000) [Pubmed]
  40. Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer. Ichiki, Y., Takenoyama, M., Mizukami, M., So, T., Sugaya, M., Yasuda, M., So, T., Hanagiri, T., Sugio, K., Yasumoto, K. J. Immunol. (2004) [Pubmed]
WikiGenes - Universities